These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8710851)

  • 1. Engineering actin-resistant human DNase I for treatment of cystic fibrosis.
    Ulmer JS; Herzka A; Toy KJ; Baker DL; Dodge AH; Sinicropi D; Shak S; Lazarus RA
    Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8225-9. PubMed ID: 8710851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus.
    Pan CQ; Dodge TH; Baker DL; Prince WS; Sinicropi DV; Lazarus RA
    J Biol Chem; 1998 Jul; 273(29):18374-81. PubMed ID: 9660804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gelsolin activates DNase I in vitro and cystic fibrosis sputum.
    Davoodian K; Ritchings BW; Ramphal R; Bubb MR
    Biochemistry; 1997 Aug; 36(32):9637-41. PubMed ID: 9289015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum.
    Tang JX; Wen Q; Bennett A; Kim B; Sheils CA; Bucki R; Janmey PA
    Am J Physiol Lung Cell Mol Physiol; 2005 Oct; 289(4):L599-605. PubMed ID: 15964901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions.
    Zahm JM; Debordeaux C; Maurer C; Hubert D; Dusser D; Bonnet N; Lazarus RA; Puchelle E
    Am J Respir Crit Care Med; 2001 Apr; 163(5):1153-7. PubMed ID: 11316652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics.
    Perks B; Shute JK
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1767-72. PubMed ID: 11069810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering hyperactive variants of human deoxyribonuclease I by altering its functional mechanism.
    Pan CQ; Lazarus RA
    Biochemistry; 1997 Jun; 36(22):6624-32. PubMed ID: 9184142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum.
    Bucki R; Sostarecz AG; Byfield FJ; Savage PB; Janmey PA
    J Antimicrob Chemother; 2007 Sep; 60(3):535-45. PubMed ID: 17584802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics.
    Broughton-Head VJ; Smith JR; Shur J; Shute JK
    Pulm Pharmacol Ther; 2007; 20(6):708-17. PubMed ID: 17055310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum.
    Bucki R; Byfield FJ; Janmey PA
    Eur Respir J; 2007 Apr; 29(4):624-32. PubMed ID: 17215317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymosin beta4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro.
    Rubin BK; Kater AP; Goldstein AL
    Chest; 2006 Nov; 130(5):1433-40. PubMed ID: 17099021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin.
    Vasconcellos CA; Allen PG; Wohl ME; Drazen JM; Janmey PA; Stossel TP
    Science; 1994 Feb; 263(5149):969-71. PubMed ID: 8310295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an analytical HPLC methodology to study the effects of thymosin β4 on actin in sputum of cystic fibrosis patients.
    Badamchian M; Damavandy AA; Goldstein AL
    Ann N Y Acad Sci; 2012 Oct; 1270():86-92. PubMed ID: 23050822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actin-Resistant DNase1L2 as a Potential Therapeutics for CF Lung Disease.
    Delfino D; Mori G; Rivetti C; Grigoletto A; Bizzotto G; Cavozzi C; Malatesta M; Cavazzini D; Pasut G; Percudani R
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33802146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of Pulmozyme activity in purulent sputum by combination with poly-aspartic acid or gelsolin.
    Bucki R; Cruz K; Pogoda K; Eggert A; Chin L; Ferrin M; Imbesi G; Hadjiliadis D; Janmey PA
    J Cyst Fibros; 2015 Sep; 14(5):587-93. PubMed ID: 25682700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin.
    Weiner DJ; Bucki R; Janmey PA
    Am J Respir Cell Mol Biol; 2003 Jun; 28(6):738-45. PubMed ID: 12600826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease.
    Sheils CA; Käs J; Travassos W; Allen PG; Janmey PA; Wohl ME; Stossel TP
    Am J Pathol; 1996 Mar; 148(3):919-27. PubMed ID: 8774146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and characterization of a DNase I-Fc fusion enzyme.
    Dwyer MA; Huang AJ; Pan CQ; Lazarus RA
    J Biol Chem; 1999 Apr; 274(14):9738-43. PubMed ID: 10092662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNase I acutely increases cystic fibrosis sputum elastase activity and its potential to induce lung hemorrhage in mice.
    Cantin AM
    Am J Respir Crit Care Med; 1998 Feb; 157(2):464-9. PubMed ID: 9476859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.